Abstract Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or
arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs …

PML-RARα oncoprotein is a fusion protein of promyelocytic leukemia (PML) and the retinoic
acid receptor-α (RARα) and causes acute promyelocytic leukemias (APL). A hallmark of all …

Autophagy is one of the main cellular catabolic pathways controlling a variety of
physiological processes, including those involved in self-renewal, differentiation and death …

Although there is evidence to suggest that PML/RARα expression is not the sole genetic
event required for the development of acute promyelocytic leukemia (APL), there is little …

The fusion oncogene, promyelocytic leukaemia (PML)–retinoic acid receptor-α (RARA),
initiates acute promyelocytic leukaemia (APL) through both a block to differentiation and …

All-trans-retinoic acid (RA) treatment induces remissions in acute promyelocytic leukemia
(APL) cases expressing the t (15; 17) product, promyelocytic leukemia (PML)/RA receptor α …

Acute promyelocytic leukemia (APL) is characterized by a specific t (15; 17) chromosomal
translocation that yields the PML/RARA fusion gene. Clinically, besides chemotherapy, two …

Background/Aim: The success of proteasome inhibitors in therapy of multiple myeloma has
led to their use for other malignancies. For the proteasome inhibitor bortezomib, combination …

PML/RAR is the leukemogenetic protein of acute promyelocytic leukemia (APL). Treatment
with retinoic acid (RA) induces degradation of PML/RAR, differentiation of leukaemic …

Acute promyelocytic leukemia (APL) is a hematological malignancy driven by the
PML/RARA oncogene. The prognosis for patients with APL was revolutionized by two …